Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Ken MasubuchiHisao ImaiSatoshi WasamotoTakeshi TsudaHiroyuki MinemuraYoshiaki NagaiYutaka YamadaTakayuki KishikawaYukihiro UmedaAyako ShionoHiroki TakechiJun ShiiharaKyoichi KairaKenya KanazawaHirokazu TaniguchiTakayuki KaburagiHiroshi KagamuKoichi MinatoPublished in: Thoracic cancer (2022)
Upon comparing OS-PFS and OS-PPS in this patient population, OS and PPS were found to have a stronger correlation. These results suggest that performance status at relapse, atezolizumab maintenance, or chemotherapy rechallenge could affect PPS.